List of Namzaric drug patents
Namzaric is owned by Allergan.
Namzaric contains Donepezil Hydrochloride; Memantine Hydrochloride.
Namzaric has a total of 19 drug patents out of which 0 drug patents have expired.
Namzaric was authorised for market use on 23 December, 2014.
Namzaric is available in capsule, extended release;oral dosage forms.
Namzaric can be used as memantine hcl/donepezil hcl combination for the treatment of moderate to severe dementia of the alzheimer's type.
The generics of Namzaric are possible to be released after 05 December, 2029.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8338485 | ALLERGAN | Compositions for the treatment of CNS-related conditions |
Nov, 2025
(2 years from now) | |
| US8173708 | ALLERGAN | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(2 years from now) | |
| US8362085 | ALLERGAN | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(2 years from now) | |
| US8338486 | ALLERGAN | Methods for the treatment of CNS-related conditions |
Nov, 2025
(2 years from now) | |
| US8283379 | ALLERGAN | Methods and compositions for the treatment of CNS-related conditions |
Nov, 2025
(2 years from now) | |
| US8580858 | ALLERGAN | Compositions for the treatment of CNS-related conditions |
Nov, 2025
(2 years from now) | |
| US8329752 | ALLERGAN | Composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(2 years from now) | |
| US8598233 | ALLERGAN | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(2 years from now) | |
| US8168209 | ALLERGAN | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(2 years from now) | |
| US8293794 | ALLERGAN | Methods and compositions for the treatment of CNS-related conditions |
Nov, 2025
(2 years from now) | |
|
US8329752
(Pediatric) | ALLERGAN | Composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(3 years from now) | |
|
US8283379
(Pediatric) | ALLERGAN | Methods and compositions for the treatment of CNS-related conditions |
May, 2026
(3 years from now) | |
|
US8173708
(Pediatric) | ALLERGAN | Method and composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(3 years from now) | |
|
US8362085
(Pediatric) | ALLERGAN | Method for administering an NMDA receptor antagonist to a subject |
May, 2026
(3 years from now) | |
|
US8598233
(Pediatric) | ALLERGAN | Method for administering an NMDA receptor antagonist to a subject |
May, 2026
(3 years from now) | |
|
US8168209
(Pediatric) | ALLERGAN | Method and composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(3 years from now) | |
| US8039009 | ALLERGAN | Modified release formulations of memantine oral dosage forms |
Mar, 2029
(6 years from now) | |
|
US8039009
(Pediatric) | ALLERGAN | Modified release formulations of memantine oral dosage forms |
Sep, 2029
(6 years from now) | |
| US8058291 | ALLERGAN | Methods and compositions for the treatment of CNS-related conditions |
Dec, 2029
(6 years from now) | |
Drugs and Companies using DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 December, 2014
Treatment: Memantine hcl/donepezil hcl combination for the treatment of moderate to severe dementia of the alzheimer's type
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
NAMZARIC family patents
70
United States
9
European Union
6
Canada
6
Japan
6
Australia
5
China
3
Brazil
3
Mexico
3
Korea, Republic of
2
Germany
2
Russia
2
Hong Kong
2
South Africa
1
Singapore
1
Spain
1
Austria
1
EA
1
Poland
1
Denmark
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic